Biophytis Advances DMD Treatment with BIO101 Scale-Up

Biophytis (BPTSY) has released an update.

Biophytis, a clinical-stage biotech company, has announced the successful scale-up of BIO101 production with Seqens, marking a significant advancement in the treatment of Duchenne Muscular Dystrophy (DMD). The first GMP-compliant batch of their lead drug candidate is now ready for use in upcoming clinical trials aimed at improving respiratory function in patients. The company is poised to start a phase 1-2 clinical trial and is actively seeking partners and funding to further this endeavor.

For further insights into BPTSY stock, check out TipRanks’ Stock Analysis page.